The Unseen Patients of Crohn's Disease NeuroScientific Biopharmaceuticals' latest news has brought a glimmer of hope to those suffering from fistulising Crohn's disease, a complication of inflammatory bowel disease that can leave patients feeling like their treatment options are dwindling.
An 80% clinical response rate in the company's StemSmart stem cell therapy trial is undeniably encouraging, but it also raises important questions about who these trials will ultimately benefit.
Those living with fistulising Crohn's disease have exhausted conventional therapies and often face a life of chronic pain, surgery, and endless medical appointments.